Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Guo, Renhua ^a   Chen, Xiaofen ^a   Wang, Tongshan ^a   Zhang, Zhiyuan ^a   Sun, Jin ^a   Shu, Yongqian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ADRENAL METASTASIS; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG ASPIRATION; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; RASH; ADJUVANT CHEMOTHERAPY; DISEASE COURSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES;

EID: 79952076802     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-90     Document Type: Article

References (24)

1. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist 2008, 13:28-36. 10.1634/theoncologist.13-S1-28, 18263772.
2. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (interest): a randomised phase III trial. Lancet 2008, 372(9652):1809-18. 10.1016/S0140-6736(08)61758-4, 19027483.
3. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Shepherd FA, . National Cancer Institute of Canada Clinical Trials Group Study BR.21 Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006, 24:3831-3837. Erratum in: J Clin Oncol 2007, 25:167, 10.1200/JCO.2006.05.8073, 16921034, National Cancer Institute of Canada Clinical Trials Group Study BR.21.
4. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G, . SATURN investigators Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529. 10.1016/S1470-2045(10)70112-1, 20493771, SATURN investigators.
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin -paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957. 10.1056/NEJMoa0810699, 19692680.
6. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98. 10.1056/NEJMoa011954, 11784875.
7. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19:3210-3218.
8. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
9. Fossella FV. Second-line chemotherapy for non-small-cell lung cancer. Curr Oncol Rep 2000, 2:96-101. 10.1007/s11912-000-0016-x, 11122830.
10. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597. 10.1200/JCO.2004.08.163, 15117980.
11. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997, 57:4838-4848.
12. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711. 10.1038/onc.2008.109, 2748240, 18408761.
13. Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, Molter J, Lam M, Flask C, Gerson S, Dowlati A, Liu L, Lee Z, Halmos B, Wang Y, Kern JA, Ma PC. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 2008, 99:911-922. 10.1038/sj.bjc.6604559, 2538758, 19238632.
14. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008, 118:2609-2619. 2430495, 18568074.
15. Kuo CH, Lin SM, Lee KY, Chung FT, Hsieh MH, Fang YF, Yu CT, Kuo HP. Subsequent Chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance. Clin Lung Cancer 2010, 11:51-56. 10.3816/CLC.2010.n.008, 20085868.
16. Li XD, Geng YT, Wu CP, Shen H, Sun J, Shu YQ, Yin YM. Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer. Onkologie 2010, 33:466-469. 10.1159/000319109, 20838064.
17. Yoshimoto A, Inuzuka K, Kita T, Kawashima A, Kasahara K. Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. Am J Med Sci 2007, 333:221-225. 10.1097/MAJ.0b013e31803b8acb, 17435415.
18. Tomizawa Y, Fujita Y, Tamura A, Shirai M, Shibata S, Kawabata T, Shibayama T, Fukai S, Kawahra M, Saito R. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer 2010, 68:269-272. 10.1016/j.lungcan.2009.06.025, 19660826.
19. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH, Miller VA. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007, 13:5150-5155. 10.1158/1078-0432.CCR-07-0560, 17785570.
20. Yokouchi H, Yamazaki K, Kinoshita I, Konishi J, Asahina H, Sukoh N, Harada M, Akie K, Ogura S, Ishida T, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007, 7:51. 10.1186/1471-2407-7-51, 1838917, 17374153.
21. Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, Yang PC. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 2005, 65:6943-6949. 10.1158/0008-5472.CAN-05-0641, 16061679.
22. Choe MS, Chen Z, Klass CM, Zhang X, Shin DM. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clin Cancer Res 2007, 13:3015-3023. 10.1158/1078-0432.CCR-06-2959, 17505004.
23. Judde JG, Rebucci M, Vogt N, de Cremoux P, Livartowski A, Chapelier A, Tran-Perennou C, Boye K, Defrance R, Poupon MF, Bras-Gonçalves RA. Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. Int J Cancer 2007, 120:1579-1590. 10.1002/ijc.22364, 17205515.
24. Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB, Johnston PG. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 2006, 5:1154-1165. 10.1158/1535-7163.MCT-05-0446, 16731747.